 |
(2-(3-(4-(1H-indazol-5-ylamino)quinazolin-2-yl)phenoxy)-N-isopropylacetamide-methane sulfonic acid salt) |
|---|---|
| Trade Name | |
| Orphan Indication | Graft Versus Host Disease |
| USA Market Approval | USA |
| USA Designation Date | 2017-10-05 00:00:00 |
| Sponsor | Kadmon Corporation, LLC;450 East 29th Street;New York, New York, 10016 |
